 |
|
BENOXINATE (DORSACAINE) FOR RAPID CORNEAL ANESTHESIA
HENRY E. SCHLEGEL, Jr., M.D.;
KENNETH C. SWAN, M.D.
AMA Arch Ophthalmol. 1954;51(5):663-670.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
THIS STUDY of the ocular pharmacology of a new drug, benoxinate (Dorsacaine), is part of a long-range program which has been directed toward finding improved methods and agents for inducing anesthesia local to the eye and its adnexa. Earlier in the program it was demonstrated that various anesthetics differ markedly in their rates of penetration of the cornea.1 The topical effectiveness of anesthetics was found to be dependent upon good penetrability of the epithelium, as well as upon anesthetic potency. Also, it was demonstrated that differences in the physical properties of drugs largely determine their relative corneal penetrability from a given vehicle. These physical properties, notably lipid solubility and surface activity, depend upon the molecular structure of the compound and are predictable to a certain extent. Anesthetic activity also is attributable to certain molecular configurations.2
These facts have simplified the search for new anesthetic drugs. A number of
. . . [Full Text PDF of this Article]
Author Affiliations
PORTLAND, ORE.
From the Department of Ophthalmology, the University of Oregon Medical School.
Footnotes
Read before the Section on Ophthalmology at the 102nd Annual Meeting of the American Medical Association, New York, June 4, 1953.
Dorsacaine for these studies was made available through the Smith-Dorsey Company, a division of The Wander Company, Lincoln, Neb.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
